Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if alternating chemotherapy with erlotinib increases
tumor shrinkage in people with metastatic colorectal cancer. The investigator will also be
studying the side effects (good and bad) of alternating chemotherapy with erlotinib on
metastatic colorectal cancer.